76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Novartis AG
Closed
117.96 0.28
Overview
Share price change
24h
Min
117.25
Max
118.42
Income | 786M 3.6B |
|---|---|
Sales | 62M 14B |
P/E Sector Avg | 18.292 51.198 |
EPS | 2.28 |
Dividend yield | 3.42 |
Profit margin | 26.476 |
Employees | 75,883 |
EBITDA | 643M 5.8B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -8.5% downside |
Dividend yield Sector Avg | 3.42% 2.40% |
|---|
Market Cap | 13B 230B |
|---|---|
Previous open | 117.68 |
Previous close | 117.96 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Novartis AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novartis AG Forecast
Price Target
By TipRanks
-8.5% downside
12 Months Forecast
Average 107 USD -8.5%
High 116 USD
Low 88 USD
Based on 5 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
